Pasithea Therapeutics Corp. (KTTAW) Stock Overview
Explore Pasithea Therapeutics Corp.’s financial performance, market position, analyst ratings, and future outlook.
Pasithea Therapeutics Corp. (KTTAW)
Key Financials
Key Financials
Market Cap
36.5K
P/E Ratio
-0.23
EPS (TTM)
$-409.13
ROE
-0.00%
KTTAW Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Pasithea Therapeutics Corp. (NASDAQ: KTTAW) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Pasithea Therapeutics Corp.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of KTTAW on the NASDAQ shows an RSI of 44.22, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Pasithea Therapeutics Corp.'s NASDAQ-traded stock include a P/E ratio of -0.23 and a market capitalization of 36.5K. Combined with our AI analysis, these give both institutional and retail investors a clear view of KTTAW on the NASDAQ.